Efficacy and Safety of Lanadelumab in pediatric Patients with hereditary Angioedema aged 2 to < 12 Years: Results of the open-label, multi-centric Phase 3 SPRING Study

被引：0

作者：

Kappek, M. ^{[1
]}

Maurer, M. ^{[2
,3
,4
,5
]}

Lumry, W. R. ^{[6
]}

Li, H. H. ^{[7
]}

Aygoeren-Pursun, E. ^{[8
]}

Busse, P. ^{[9
]}

Jacobs, J. ^{[10
,11
]}

Nurse, C. ^{[11
]}

机构：

[1] Takeda Pharma Vertrieb GmbH Co KG, Med Affairs, Berlin, Germany

[2] Charite Univ Med Berlin, Berlin, Germany

[3] Free Univ Berlin, Berlin, Germany

[4] Humboldt Univ, Inst Allergol, Berlin, Germany

[5] Fraunhofer Inst Translat Med & Pharmacol ITMP, Allergol & Immunol, Berlin, Germany

[6] Allergy & Asthma Res Associates, Dallas, TX USA

[7] Inst Asthma & Allergy, Chevy Chase, MD USA

[8] Goethe Univ, Univ Krankenkaus Frankfurt, Klin Kinder & Jugendmed, Angioodem & HAE Ambulanz, Frankfurt, Germany

[9] Icahn Sch Med Mt Sinai, Div Allergy & Clin Immunol, New York, NY USA

[10] Allergy & Asthma Clin Res, Walnut Creek, CA USA

[11] Takeda Dev Ctr Amer, Lexington, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

P8.09

引用

页码：560 / 560

页数：1